Nuwellis completes acquisition of Rendiatech

Nuwellis, Inc. has completed its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology.

Rhea-AI Filing Summary

Nuwellis, Inc. has completed its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology. This technology is designed to support clinical decision-making for critically ill patients, potentially broadening Nuwellis’ clinical offerings in advanced patient monitoring.

Insights

Medical devices M&A analyst

Nuwellis closes a strategic acquisition adding kidney monitoring technology to its portfolio.

Nuwellis has closed the acquisition of Rendiatech, an Israeli developer of automated kidney function monitoring technology for critically ill patients. This adds a complementary capability focused on real-time kidney function insights to support clinical decision-making.

The move suggests a strategic push deeper into critical care monitoring rather than only therapeutic devices. The actual financial impact depends on integration success, commercialization progress, and how quickly hospitals adopt Rendiatech’s technology, details that are not described in this excerpt.

Subsequent disclosures in company filings may clarify deal terms, integration plans, and any contribution to revenue, which will help investors assess how meaningful Rendiatech becomes within Nuwellis’ broader product and service mix.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Nuwellis (NUWE) report in this 8-K filing?

Nuwellis reported the closing of its previously announced acquisition of Rendiatech, Inc. The deal adds an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients to Nuwellis’ operations.

Who is Rendiatech in the Nuwellis (NUWE) acquisition disclosure?

Rendiatech, Inc. is described as an Israeli-based developer of automated kidney function monitoring technology. Its products are designed to support clinical decision-making in critically ill patients, broadening Nuwellis’ focus on technologies used in intensive care settings.

When did Nuwellis (NUWE) complete the acquisition of Rendiatech?

Nuwellis stated that on March 17, 2026, it announced the closing of its previously announced acquisition of Rendiatech, Inc. This date marks the completion of the transaction as disclosed in the current report on Form 8-K.

What type of technology did Nuwellis gain through the Rendiatech acquisition?

Through acquiring Rendiatech, Nuwellis gained automated kidney function monitoring technology. This technology is intended to support clinical decision-making for critically ill patients, indicating a focus on tools that help clinicians assess and manage kidney function in high-acuity settings.

Where is Rendiatech, the company acquired by Nuwellis (NUWE), based?

Rendiatech, Inc. is described as an Israeli-based company. Its primary focus is developing automated kidney function monitoring technology aimed at supporting clinical decisions for critically ill patients, which now becomes part of Nuwellis’ broader medical technology portfolio.

Who signed the Nuwellis (NUWE) report confirming the Rendiatech acquisition closing?

The report confirming the closing of the Rendiatech acquisition was signed on behalf of Nuwellis by John L. Erb. He is identified as the company’s President and Chief Executive Officer, acting as the authorized signatory for the registrant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 09:13 AM EDT Learn about SEC filing dates

false0001506492MNNASDAQ00015064922026-03-172026-03-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

Nuwellis, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-35312	No. 68-0533453
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
12988 Valley View Road, Eden Prairie, MN (Address of Principal Executive Offices)		55344 (Zip Code)

(952) 345-4200

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	NUWE	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On March 17, 2026, Nuwellis, Inc. (the “Company”) announced the closing of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 17, 2026	NUWELLIS, INC.
	By:	/s/ John L. Erb
	Name:	John L. Erb
	Title:	President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB